EICHORCondition: Extensive Stage Small Cell Lung Cancer · Sponsor: Amgen
The primary aim of this study is to evaluate the efficacy of tarlatamab as assessed by objective response rate (ORR) based on blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1).
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Beijing Cancer Hospital | Beijing, Beijing Municipality, China | — |
| The Second Affiliated Hospital of Army Medical University, People's Liberation Army | Chongqing, Chongqing Municipality, China | — |
| Army Special Medical Center of Peoples Liberation Army | Chongqing, Chongqing Municipality, China | — |
| Mengchao Hepatobiliary Hospital of Fujian Medical University | Fuzhou, Fujian, China | — |
| Sun Yat-Sen University Cancer Center | Guangzhou, Guangdong, China | — |
| Jiangmen Central Hospital | Jiangmen, Guangdong, China | — |
| Harbin Meidical University Cancer Hospital | Harbin, Heilongjiang, China | — |
| Tongji Hospital Tongji Medical College Huazhong University of Science and Technology | Wuhan, Hubei, China | — |
| Tianjin Medical University General Hospital | Tianjin, Tianjin Municipality, China | — |
| The Second Affiliated Hospital of Zhejiang University School of Medicine | Hangzhou, Zhejiang, China | — |
| Taizhou Hospital of Zhejiang Province | Linhai, Zhejiang, China | — |
| Fujian Cancer Hospital | Fuzhou, China | — |
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06502977